Cited 56 times in
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2018-07-20T07:50:46Z | - |
dc.date.available | 2018-07-20T07:50:46Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2093-582X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160578 | - |
dc.description.abstract | PURPOSE: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. MATERIALS AND METHODS: We pooled data from patients randomized between 2009 and 2012 in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced gastric or GEJ adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing therapy (REGARD and RAINBOW). Forty-one key baseline clinical and laboratory factors common in both studies were examined. Model building started with covariate screening using univariate Cox models (significance level=0.05). A stepwise multivariable Cox model identified the final prognostic factors (entry+exit significance level=0.01). Cox models were stratified by treatment and geographic region. The process was repeated to identify baseline prognostic quality of life (QoL) parameters. RESULTS: Of 1,020 randomized patients, 953 (93%) patients without any missing covariates were included in the analysis. We identified 12 independent prognostic factors of poor survival: 1) peritoneal metastases; 2) Eastern Cooperative Oncology Group (ECOG) performance score 1; 3) the presence of a primary tumor; 4) time to progression since prior therapy <6 months; 5) poor/unknown tumor differentiation; abnormally low blood levels of 6) albumin, 7) sodium, and/or 8) lymphocytes; and abnormally high blood levels of 9) neutrophils, 10) aspartate aminotransferase (AST), 11) alkaline phosphatase (ALP), and/or 12) lactate dehydrogenase (LDH). Factors were used to devise a 4-tier prognostic index (median overall survival [OS] by risk [months]: high=3.4, moderate=6.4, medium=9.9, and low=14.5; Harrell's C-index=0.66; 95% confidence interval [CI], 0.64-0.68). Addition of QoL to the model identified patient-reported appetite loss as an independent prognostic factor. CONCLUSIONS: The identified prognostic factors and the reported prognostic index may help clinical decision-making, patient stratification, and planning of future clinical studies. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Gastric Cancer Association | - |
dc.relation.isPartOf | JOURNAL OF GASTRIC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Charles S. Fuchs | - |
dc.contributor.googleauthor | Kei Muro | - |
dc.contributor.googleauthor | Jiri Tomasek | - |
dc.contributor.googleauthor | Eric Van Cutsem | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.contributor.googleauthor | Sang-Cheul Oh | - |
dc.contributor.googleauthor | Howard Safran | - |
dc.contributor.googleauthor | György Bodoky | - |
dc.contributor.googleauthor | Ian Chau | - |
dc.contributor.googleauthor | Yasuhiro Shimada | - |
dc.contributor.googleauthor | Salah-Eddin Al-Batran | - |
dc.contributor.googleauthor | Rodolfo Passalacqua | - |
dc.contributor.googleauthor | Atsushi Ohtsu | - |
dc.contributor.googleauthor | Michael Emig | - |
dc.contributor.googleauthor | David Ferry | - |
dc.contributor.googleauthor | Kumari Chandrawansa | - |
dc.contributor.googleauthor | Yanzhi Hsu | - |
dc.contributor.googleauthor | Andreas Sashegyi | - |
dc.contributor.googleauthor | Astra M. Liepa | - |
dc.contributor.googleauthor | Hansjochen Wilke | - |
dc.identifier.doi | 10.5230/jgc.2017.17.e16 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J01415 | - |
dc.identifier.eissn | 2093-5641 | - |
dc.identifier.pmid | 28680718 | - |
dc.subject.keyword | Gastroesophageal junction | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Stomach neoplasms | - |
dc.subject.keyword | Survival | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | Cho, Jae Yong | - |
dc.citation.volume | 17 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 132 | - |
dc.citation.endPage | 144 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTRIC CANCER, Vol.17(2) : 132-144, 2017 | - |
dc.identifier.rimsid | 48977 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.